Article Text

PDF
Letter
Serum macrophage inflammatory protein 3α levels predict the severity of HBV-related acute-on-chronic liver failure
  1. Jiaojiao Xin1,
  2. Wenchao Ding2,
  3. Shaorui Hao1,
  4. Xin Chen3,
  5. Jianing Zhang3,
  6. Longyan Jiang1,
  7. Qian Zhou1,
  8. Dongyan Shi1,
  9. Liyuan Zhang1,
  10. Xiaowei Xu1,
  11. Hongcui Cao1,
  12. Lanjuan Li1,
  13. Jun Li1
  1. 1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
  2. 2 Systems Biology Division, Zhejiang–California International Nanosystems Institute, Zhejiang University, Hangzhou, China
  3. 3 Department of Bioinformatics, College of Life Sciences, Zhejiang University, Hangzhou, China
  1. Correspondence to Professor Jun Li, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd, Hangzhou 31000, China; lijun2009{at}zju.edu.cn

Statistics from Altmetric.com

Dear Editor,

We read with interest the paper by Angeli et al 1 proposing the value of the acute-on-chronic liver failure (ACLF) stratification in the prediction of short-term mortality in patients with acute decompensation of cirrhosis. Other studies2 ,3 indicated that the dynamic changes in serological markers are associated with patients who have cirrhosis. We hypothesised that the pathological processes of HBV-related ACLF (HBV-ACLF) would result in specific changes in the levels of signalling proteins in the blood. Thus, we aimed to search detectable biomarkers to predict the outcome of HBV-ACLF.

We collected serum samples from 420 patients with HBV-ACLF, 121 patients with chronic hepatitis B (CHB) and 25 normal controls to identify novel serological biomarkers of HBV-ACLF (see online supplementary table S1). As an initial screening group, 15 subjects were included in the cytokine antibody array analyses (n=5 per group). The remaining 551 subjects were included in the ELISA measurement group. The enrolment criteria for the patients with HBV-ACLF corresponded to the previously published the chronic liver failure-sequential organ failure assessment (CLIF-SOFA) score.4

The bioinformatics analyses of …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.